ArticleBlood2013
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Trial
- Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment.Blood cancer discovery · 2024Review
- Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER Database.Medical sciences (Basel, Switzerland) · 2024Article
- Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.Blood advances · 2024Article
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.American journal of hematology · 2024Review
- Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia.Blood · 2023Article
- Inherited heterozygous Fanconi anemia gene mutations in a therapy-related CMML patient with a rareFrontiers in oncology · 2022Article
- Mutations in chronic myelomonocytic leukemia and their prognostic relevance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil.Clinical case reports · 2021Article
- Massive Right Atrial Thrombosis: Are You Brave Enough to Start Anticoagulation? A Case Report.Frontiers in cardiovascular medicine · 2021Article
- Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.British journal of haematology · 2020Article
- Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years.Blood advances · 2019Article
- Review
- Chronic myelomonocytic leukemia as a transformation from polycythemia vera.Leukemia research reports · 2019Article
- Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.American journal of hematology · 2018Article
- Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.American journal of hematology · 2018Review
- CMML: Clinical and molecular aspects.International journal of hematology · 2017Review
- Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Current hematologic malignancy reports · 2015Review
- Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Current treatment options in oncology · 2015Review
- Chronic myelomonocytic leukemia: Forefront of the field in 2015.Critical reviews in oncology/hematology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
We sought to describe the clinical features and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those of de novo CMML. We identified 358 CMML patients, of whom 39 (11%) had t-CMML. Although the groups had similar demographic, hematologic, and molecular alteration profiles, the proportion of patients with intermediate or high CMML-specific cytogenetic risk in the t-CMML was significantly higher than that in the de novo CMML (P = .011). The median latency to develop t-CMML was 6 years. The median overall and leukemia-free survival duration of the t-CMML were shorter than those of the de novo CMML; however, t-CMML itself was not prognostic after adjusting for the effects of other covariates including cytogenetics. These results suggest that compared with de novo CMML, t-CMML is associated with more high-risk cytogenetics that manifest as poor outcomes. We propose that t-CMML be recognized as one of the therapy-related myeloid neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.